National trends in acute lymphocytic leukemia (ALL) incidence (1999–2021): A longitudinal outcome study using joinpoint analysis of age, sex, and regional disparities

M Muzamil Khan (The George Washington University, Washington, District of Columbia, United States) U Ummul Asfeen (5MD Anderson Cancer Center, Hospice Palliative Medicine, Houston, United States) A Ayesha Cheema (Al Tibri Medical College, Karachi, Pakistan) W Wajdan Ahmad (Al-Tibri Medical College, Karachi, Pakistan) A Anika Goel (Kakatiya Medical College, Telangana, Hyderabad, India) W Waseem Nabi (5University Florida, Gainsville, United States) N Nouman Aziz (6Wyckoff Heights Medical Center, Brooklyn, United States) S Swetha Balaji (New York Medical College at St. Mary’s Hospital and St. Clare’s Health, Denville, New Jersey, United States) A Amara Sofia (New York Medical College at St. Mary’s Hospital and St. Clare’s Health, Denville, New Jersey, United States) K Khadija Mohib (Kirk Kerkorian School of Medicine, Las vegas, Nevada, United States) A Amar Lal (9Penn State Health Milton S Hershey Medical, Hershey, United States) A Arshaman Ul Haq (10Omar Hospital, Karachi, Pakistan)

Abstract

Abstract INTRODUCTION Acute Lymphocytic Leukemia (ALL) is a highly aggressive hematological malignancy characterized by rapid proliferation of lymphoid progenitor cells, requiring prompt diagnosis and intensive treatment to achieve optimal outcomes. This study systematically investigates the incidence trends from 1999 to 2021, with a particular focus on demographic and regional disparities. Method: The data for this study were sourced from the Centers for Disease Control and Prevention (CDC) Wonder Database. This dataset includes the incidence rates of ALL across various age groups: under 1 year, 5-9 years, 10-14 years, 15-19 years, 20-24 years, 25-29 years, 30-34 years, 35-39 years, 40-44 years, 45-49 years, 50-54 years, 55-59 years, 60-64 years, 65-69 years, 70-74 years, 75-79 years, 80-84 years, and 85 years and older. Each year's incidence rates are expressed per 100,000 population. To determine the percentage increase, the incidence rates from 1999 were compared with those from 2021. Joinpoint regression was used to estimate average annual percent change (AAPC) with 95% confidence intervals. RESULTS From 1999 to 2021, there were 111133 reported cases of ALL. Throughout this period, the overall incidence rate showed an increase by 34.75% over two decades. This corresponds to an AAPC of 0.9073 with a 95%CI of 0.7191 (1.0958 - 10.0618) and P value < 0.000001. When examining the data by gender, men experienced lower incidence rates than women, with an incidence rate of 33.196% for men and 36.82% for women. The AAPC for women was 1.0002 with 95% CI (0.7672 - 1.2338 ), while for men, it was 0.9681 with 95% CI (0.7562 -1.1805). When looking at racial groups, Blacks or African Americans showed the greatest increase in incidence rates with AAPC of 0.8035 with 95% CI of (0.3479 - 1.2612) followed by Asian or Pacific Islanders with an AAPC of 0.7639 with 95% CI (0.2581 -1.2723), compared to other races, When it comes to regions, Southern USA had the highest incidence rate with an AAPC of 1.1902 95% CI (0.9556 - 1.4255). Age-specific trends revealed that the 1-4 year age group saw the largest relative increase in incidence, surging by 26972 with a crude incidence rate of 7.47, with the sharpest decline in later age groups until 55-59. Surprisingly, after 55-59, it started rising again from age groups 60-64 until 80-84. After age 85, however, the incidence rates started decreasing once again. CONCLUSION Incidence of ALL in children is obvious, but it has also significantly increased across the U.S. adult population, particularly after 59, with disparities most pronounced by sex, race/ethnicity & region. Targeted interventions are needed to address disparities and mitigate rising incidence rates.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue Supplement 1
Published November 03, 2025
Pages 8040-8040
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (12)

M

Muzamil Khan

The George Washington University, Washington, District of Columbia, United States

U

Ummul Asfeen

5MD Anderson Cancer Center, Hospice Palliative Medicine, Houston, United States

A

Ayesha Cheema

Al Tibri Medical College, Karachi, Pakistan

W

Wajdan Ahmad

Al-Tibri Medical College, Karachi, Pakistan

A

Anika Goel

Kakatiya Medical College, Telangana, Hyderabad, India

W

Waseem Nabi

5University Florida, Gainsville, United States

N

Nouman Aziz

6Wyckoff Heights Medical Center, Brooklyn, United States

S

Swetha Balaji

New York Medical College at St. Mary’s Hospital and St. Clare’s Health, Denville, New Jersey, United States

A

Amara Sofia

New York Medical College at St. Mary’s Hospital and St. Clare’s Health, Denville, New Jersey, United States

K

Khadija Mohib

Kirk Kerkorian School of Medicine, Las vegas, Nevada, United States

A

Amar Lal

9Penn State Health Milton S Hershey Medical, Hershey, United States

A

Arshaman Ul Haq

10Omar Hospital, Karachi, Pakistan